Glaukos (NYSE:GKOS) CEO Thomas William Burns Sells 88,055 Shares

Glaukos Corporation (NYSE:GKOS) CEO Thomas William Burns sold 88,055 shares of Glaukos stock in a transaction dated Thursday, January 8th. The stock was sold at an average price of $115.00, for a total transaction of $10,126,325.00. Following the transaction, the chief executive officer directly owned 153,775 shares in the company, valued at $17,684,125. This trade represents a 36.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Thomas William Burns also recently made the following trade(s):

• On Friday, January 16th, Thomas William Burns sold 186,945 shares of Glaukos stock. The shares were sold at an average price of $115.00, for a total transaction of $21,498,675.00.

Glaukos Stock Up 2.5%

Shares of NYSE GKOS opened at $123.19 on Wednesday. The company has a market capitalization of $7.08 billion, a P/E ratio of -79.99 and a beta of 0.67. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.20 and a quick ratio of 4.47. The company has a 50 day simple moving average of $108.62 and a 200-day simple moving average of $95.74. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $163.71.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.52% and a negative net margin of 18.65%.The company had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same period in the prior year, the business posted ($0.28) earnings per share. The firm’s revenue for the quarter was up 38.1% compared to the same quarter last year. On average, equities research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.

Institutional Investors Weigh In On Glaukos

Several large investors have recently added to or reduced their stakes in GKOS. AQR Capital Management LLC lifted its holdings in Glaukos by 2.6% during the 1st quarter. AQR Capital Management LLC now owns 7,788 shares of the medical instruments supplier’s stock worth $766,000 after buying an additional 198 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Glaukos by 1,405.9% during the first quarter. Jones Financial Companies Lllp now owns 2,560 shares of the medical instruments supplier’s stock worth $252,000 after acquiring an additional 2,390 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Glaukos by 41.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 229,994 shares of the medical instruments supplier’s stock valued at $22,636,000 after acquiring an additional 67,668 shares in the last quarter. Assenagon Asset Management S.A. purchased a new position in Glaukos in the second quarter valued at $1,245,000. Finally, Diversified Trust Co purchased a new position in Glaukos in the second quarter valued at $434,000. 99.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the stock. Truist Financial upped their target price on shares of Glaukos from $120.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, December 18th. BTIG Research reissued a “buy” rating and issued a $116.00 price target on shares of Glaukos in a research note on Friday, January 2nd. Citigroup upped their price objective on shares of Glaukos from $113.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, December 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus set a $115.00 target price on Glaukos in a research report on Monday, October 27th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $127.92.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.